Literature DB >> 11307155

Up-regulation of thioredoxin and thioredoxin reductase in human malignant pleural mesothelioma.

K Kahlos1, Y Soini, M Säily, P Koistinen, S Kakko, P Pääkkö, A Holmgren, V L Kinnula.   

Abstract

Thioredoxin (Trx) with a redoxactive dithiol together with NADPH and thioredoxin reductase (TrxR) is a major disulfide reductase regulating cellular redox state and cell proliferation and possibly contributing to the drug resistance of malignant cells. We assessed the Trx system in malignant pleural mesothelioma cell lines, in nonmalignant pleural mesothelium and in biopsies of malignant pleural mesothelioma. The mRNA and immunoreactive proteins of Trx and cytosolic and mitochondrial TrxR were positive in all four human mesothelioma cell lines investigated. Six cases of nonmalignant, histologically healthy pleural mesothelium showed no Trx or TrxR immunoreactivity, whereas immunohistochemistry on 26 biopsies of human malignant pleural mesothelioma showed positive Trx in all cases and positive TrxR in 23 (88%) of the cases. Moderate or strong immunoreactivity for Trx or TrxR was detected in 85% (22 cases) and 61% (14 cases) of the mesothelioma cases, respectively. Both Trx and TrxR staining patterns were mainly diffuse and cytoplasmic, but in 39% of the mesothelioma cases prominent nuclear staining could also be detected. Although staining for Trx and TrxR was seen in tumor cells, no significant association could be demonstrated between Trx or TrxR expression and tumor cell proliferation or apoptosis in the biopsies of mesothelioma. There was no significant association between the intensity of Trx or TrxR immunoreactivity and patient survival, which may possibly be related to moderate or intense Trx and TrxR reactivity in most of the cases. Although the Trx system may have an important role in the drug resistance of malignant mesothelioma, these studies also suggest that multiple factors contribute to the promotion, cell proliferation and apoptosis of malignant mesothelioma cells in vivo. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11307155     DOI: 10.1002/1097-0215(20010520)95:3<198::aid-ijc1034>3.0.co;2-f

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  19 in total

1.  Inhibition of thioredoxin reductase 1 by porphyrins and other small molecules identified by a high-throughput screening assay.

Authors:  Stefanie Prast-Nielsen; Thomas S Dexheimer; Lena Schultz; William C Stafford; Qing Cheng; Jianqiang Xu; Ajit Jadhav; Elias S J Arnér; Anton Simeonov
Journal:  Free Radic Biol Med       Date:  2011-01-22       Impact factor: 7.376

Review 2.  The emerging role of the thioredoxin system in angiogenesis.

Authors:  Louise L Dunn; Andrew M Buckle; John P Cooke; Martin K C Ng
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-08-26       Impact factor: 8.311

3.  Thioredoxin reductase 3 suppression promotes colitis and carcinogenesis via activating pyroptosis and necrosis.

Authors:  Qi Liu; Pengyue Du; Yue Zhu; Xintong Zhang; Jingzeng Cai; Ziwei Zhang
Journal:  Cell Mol Life Sci       Date:  2022-01-30       Impact factor: 9.261

4.  Thioredoxin-related mechanisms in hyperoxic lung injury in mice.

Authors:  Trent E Tipple; Stephen E Welty; Lynette K Rogers; Thomas N Hansen; Young-Eun Choi; James P Kehrer; Charles V Smith
Journal:  Am J Respir Cell Mol Biol       Date:  2007-06-15       Impact factor: 6.914

5.  Identification of Michael acceptor-centric pharmacophores with substituents that yield strong thioredoxin reductase inhibitory character correlated to antiproliferative activity.

Authors:  Fei-Fei Gan; Kamila K Kaminska; Hong Yang; Chin-Yee Liew; Pay-Chin Leow; Choon-Leng So; Lan N L Tu; Amrita Roy; Chun-Wei Yap; Tse-Siang Kang; Wai-Keung Chui; Eng-Hui Chew
Journal:  Antioxid Redox Signal       Date:  2013-02-28       Impact factor: 8.401

6.  Up-regulation of the redox mediators thioredoxin and apurinic/apyrimidinic excision (APE)/Ref-1 in hypoxic microregions of invasive cervical carcinomas, mapped using multispectral, wide-field fluorescence image analysis.

Authors:  David Hedley; Melania Pintilie; Jennifer Woo; Trudey Nicklee; Andrew Morrison; Diana Birle; Anthony Fyles; Michael Milosevic; Richard Hill
Journal:  Am J Pathol       Date:  2004-02       Impact factor: 4.307

7.  A novel thioredoxin reductase inhibitor inhibits cell growth and induces apoptosis in HL-60 and K562 cells.

Authors:  Zuo-Fu Peng; Lin-Xiang Lan; Fang Zhao; Jing Li; Qiang Tan; Han-Wei Yin; Hui-Hui Zeng
Journal:  J Zhejiang Univ Sci B       Date:  2008-01       Impact factor: 3.066

8.  Regulation of the bioavailability of thioredoxin in the lens by a specific thioredoxin-binding protein (TBP-2).

Authors:  Namal P M Liyanage; M Rohan Fernando; Marjorie F Lou
Journal:  Exp Eye Res       Date:  2007-05-21       Impact factor: 3.467

9.  Altered expression of thioredoxin reductase-1 in dysplastic bile ducts and cholangiocarcinoma in a hamster model.

Authors:  Byung Il Yoon; Dae Yong Kim; Ja June Jang; Jeong Hee Han
Journal:  J Vet Sci       Date:  2006-09       Impact factor: 1.672

10.  Peroxiredoxin 3 is a redox-dependent target of thiostrepton in malignant mesothelioma cells.

Authors:  Kheng Newick; Brian Cunniff; Kelsey Preston; Paul Held; Jack Arbiser; Harvey Pass; Brooke Mossman; Arti Shukla; Nicholas Heintz
Journal:  PLoS One       Date:  2012-06-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.